3 results
Approved WMOPending
Primary Objective: The primary objective is to evaluate the efficacy of daratumumab plus CyBorD compared with CyBorDalone in the treatment of newly diagnosed AL amyloidosis patients.Secondary Objectives:# To evaluate the clinically observable…
Approved WMOCompleted
To demonstrate superiority with regard to Progression Free Survival based on an Independent Review Committeeassessment of avelumab versus platinum-based doublet in NSCLC subjects with PD-L1+
Approved WMORecruiting
Primary objective: To determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared to active monitoring in subjects with high-risk smoldering multiple myeloma (SMM).Secondary…